Successful treatment of juvenile-onset HLA-B27-associated severe and refractory heel Thesitis with adalimumab documented by magnetic resonance imaging SIR, Severe and therapy-resistant heel enthesitis is a challenging and complicated problem in the spondyloarthritis (SpA) field [1] . Recently D'Agostino et al. [2] have successfully treated with infliximab two patients suffering from long-standing refractory HLA-B27-associated heel enthesitis. They have documented the response to the therapy by using ultrasonography. We have treated a similar patient with adalimumab and documented the positive results by magnetic resonance imaging (MRI).
The patient was a 16-yr-old HLA-B27-positive boy. His disease began 9 months before with pain at insertion of the left Achilles tendon. Subsequently, there was the involvement of the insertion of the left plantar fascia. Pain did not respond to adequate trials (3 months at full doses) of nimesulide and diclofenac. The patient stopped all physical and sport activity due to the severity of his heel pain. His medical history did not reveal any other clinical manifestation of the HLA-B27-associated disease.
Physical examination showed pain at the insertion of the left Achilles tendon and plantar fascia. The level of pain on a 100-point VAS was 83.
Pelvic and foot radiographs were normal. MRI of the left foot showed a slight swelling of the insertion of the left Achilles tendon and plantar fascia and a distension of the retrocalcaneal bursa by fluid collection together with a diffuse bone oedema of the left calcaneus (Fig. 1A) . Laboratory evaluation showed a C-reactive protein (CRP) level of 29.9 mg/l (normal <5).
Considering the severity of the situation, we decided to treat the patient with adalimumab at a dose of 40 mg fortnightly after obtaining his parents' written, informed consent. The day after the first subcutaneous injection, pain in the heel disappeared completely. CRP normalized after 15 days. MRI obtained 25 days (Fig. 1B ) and 50 days (Fig. 1C) after the beginning of therapy showed a marked progressive improvement of the oedema. Two months after the start of therapy we had to decide whether to give more importance to the clinical situation (the patient had no pain) or the persistence of the MRI findings. We decided to continue with adalimumab until a marked improvement of the MRI findings. This happened after 5 months from the beginning of the therapy (Fig. 1D) , when we stopped the drug. The disease remained in remission in the following 15 months. New MRIs obtained after 3 ( Fig. 1E ) and 8 months (Fig. 1F ) from the end of adalimumab therapy documented a further improvement of the bone oedema.
Our patient suffered from undifferentiated SpA (uSpA) starting and evolving with isolated severe and refractory peripheral enthesitis [3] . Amor et al. [1] consider enthesitis refractory to therapy only when it persisted for more than 2 yrs despite conventional treatment including NSAIDs, steroid injections, sulphasalazine, methotrexate and radiotherapy. Braun and Sieper [4] have recently suggested that six months is a sufficient period to try every conventional treatment. In the past, we would have treated the present patient with steroid injections. We did not because MRI showed a diffuse oedema of all the calcaneus that should probably have not responded to steroids injected only near the insertion of the plantar fascia and into the retrocalcaneal bursa. After the failure of the local therapy, we would have treated him with sulfasalazine and, in case of insufficient response, we would have added methotrexate. These therapies need time to be effective, and we did not want our patient to continue to have pain for another 3 or 4 months. On the other hand, the efficacy of these drugs on peripheral enthesitis relies only on studies of a limited numbers of cases. So, we decided start anti-tumour necrosis factor-(TNF) therapy, which has been shown to ameliorate the bone oedema due to enthesitis, which is visible on MRI both in the spine as well as in the limbs [5, 6] . Recently D'Agostino et al. [2] have successfully treated two patients with B27-associated refractory heel enthesitis with infliximab. They have monitored the regression of enthesitis by using ultrasonography coupled with power Doppler ultrasound. This examination assesses entheseal inflammation by measuring increased blood flow due to neovascularization. We have treated our patient with adalimumab, which a recent open study has demonstrated to be useful in SpA [7] . We have monitored the regression of enthesitis using MRI. If we had used power Doppler ultrasound, we would have missed the diffuse bone oedema of the calcaneus. Waiting for a marked improvement of the bone oedema was crucial for interrupting the therapy without having the recurrence of the clinical symptoms of enthesitis. The role of MRI and ultrasound in monitoring the response to therapy of enthesitis should be the objective of future studies. Probably both should be performed.
In conclusion, our experience suggests that a short course of anti-TNF therapy can cure severe and resistant HLA-B27-associated enthesitis and that MRI can be useful in deciding when to interrupt the therapy. Onset of systemic lupus erythematosus after conversion of infliximab to adalimumab treatment in rheumatoid arthritis with a pre-existing anti-dsDNA antibody level SIR, Drug-induced systemic lupus erythematosus (SLE) has been described for rheumatoid arthritis (RA) patients treated with the tumour necrosis factor-(TNF-)-blocking agents, infliximab and etanercept [1, 2] . This complication of clinically manifest SLE seems to be induced considerably less often, if not at all, in patients treated with the fully human anti-TNF-antibody, termed adalimumab [3] . The present case report describes a patient who develops SLE upon conversion of infliximab to adalimumab and provides data that indicate the involvement of a Th1-driven inflammatory response in this patient.
A 56-yr-old Asiatic woman with a 26-yr-old history of severe disabling RA was previously unsuccessfully treated with hydroxychloroquine, D-penicillamine, azathioprine, prednisone and methotrexate. Rheumatoid factor was always strongly positive whereas anti-nuclear and anti-dsDNA antibody levels were not detectable.
In November 2001, TNF-blocking treatment was started (infliximab: 3 mg/kg, once i.v. per 8 weeks) which induced a good clinical response. Gradually the clinical response waned; the effect of an infliximab-infusion lasted only 2-3 weeks. Therefore, after %2 yrs and a wash-out period of 8 weeks, this patient was switched to subcutaneous adalimumab 40 mg every other week (written consent of the patient was obtained according to the declaration of Helsinki and the design of the adalimumab study was approved by the UMC, Utrecht medical ethical committee).
At the start of adalimumab treatment, active polyarthritis was associated with a positive anti-nuclear antibodies (ANA) and an anti-dsDNA titre of 245 IU/ml (Farr assay, normal range 0-10 IU/ml, Fig. 1A ). These levels were raised during infliximab therapy since prior to infliximab therapy the level was 4 IU/ml. Despite this rise, apart, from arthritis, no clinical signs of SLE were present. The severe polyarthritis was rapidly reduced as indicated by the significant decreases in joint swelling and tenderness. After four bi-weekly injections she developed severe ulcerations of the buccal mucosa and the palatum. Five injections later, she was admitted to the hospital with fever, high erythrocyte sedimentation rate (ESR), leucopenia, anaemia and a photosensitive urticarial and papulosquamous rash on the exposed areas of her face and felt generally lethargic (Fig. 1A) . Cultures of blood and urine were negative; a crista biopsy revealed no abnormalities. Skin biopsy at this time point (week 18) revealed vacuolization of basal keratinocytes with subepidermal blistering and a superficial and deep lymphocytic infiltrate consistent with lupus erythematosus (LE) (Fig. 1B) . At this time point, strongly increased anti-dsDNA antibody levels were observed (Fig. 1A) . A diagnosis of SLE was made and her adalimumab treatment was discontinued. She received three i.v. injections of 200 mg dexamethasone every other day. The patient generally felt better; the mucosal ulcerations and skin lesions disappeared. In contrast to this, anti-dsDNA levels were not reduced by dexamethasone pulse treatment.
The immunopathological mechanism for the development of SLE upon anti-TNF-therapy is unclear. In animal models for SLE, the development of experimental SLE was suggested to involve two stages: increased Th1-driven [interferon-(IFN), interleukin (IL-2)] inflammatory responses including antibody formation, followed by 'Th2' cell responses (IL-4, IL-10) with persistent antibody levels [4] . Based on serum protein levels of patients with SLE, in particular, those who suffer from active disease, several studies have suggested the involvement of cytokines that induce Th1 responses [migration inhibitory factor (MIF), IL-12, IL-18] as well as Th1 activity itself (IFN, IL-2, IL-17) [5] [6] [7] . Along with the presence of this type of immune response, Th2 cell activity (IL-4) as well as IL-10 levels have been found to be increased and were found to correlate with markers of inflammation such as anti-dsDNA [6, 7] .
To understand the anti-TNF--induced SLE immunopathology, serum cytokine levels were assessed in retrospect which could explain the development of this clinical finding. Interestingly, associated with a rise in ESR, adalimumab treatment strongly increased cytokines indicative of Th1 activity in contrast to 'anti-inflammatory' and Th2-associated cytokines, which were not significantly changed (Fig. 1C and D) . In RA patients, the increase of systemic Th1 activity upon anti-TNF-treatment can occur due to re-entry of inflammatory cells from the site of inflammation (joints) into the circulation or due to repression of TNF--inhibited Th1 activity [8, 9] . However, this is usually associated with decreased inflammation as indicated by decreased C-reactive protein (CRP) and ESR. In the presented patient, the development of skin inflammation and increased antibody levels could explain a rise in markers of inflammation such as ESR.
In contrast to the induction of antoantibodies, the clinical presentation of (biopsy-confirmed) active SLE upon adalimumab therapy is rarely, if at all, reported. As far as we know, this is the first article describing the biopsy-confirmed development of clinical SLE upon adalimumab treatment following infliximab therapy. Since infliximab treatment had already induced high anti-dsDNA levels, adalimumab treatment seems to have boosted the infliximab-induced mechanisms that were accompanied by pro-inflammatory activity. Finally, this may develop into the clinical presentation of SLE. Therefore caution may have to be taken when anti-dsDNA antibodies are present at the start of conversion therapy.
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Key message
Increased cytokine and anti-dsDNA levels accompany SLE development upon infliximab-adalimumab conversion.
